Cellular immune response to the anti-SARS-CoV-2 BNT162b2 mRNA vaccine in pediatric autoimmune inflammatory rheumatic disease patients and controls

This paper aims to compare the cellular immune response to the SARS-CoV-2 BNT162b2 vaccine of pediatric patients with autoimmune inflammatory rheumatic disease (pAIIRD) and healthy controls. A prospective longitudinal study was conducted between April 2021 and December 2022 at the Tel Aviv Medical C...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental immunology 2024-07, Vol.217 (2), p.167-172
Main Authors: Eviatar, Tali, Pappo, Adi, Freund, Tal, Friedlander, Yishai, Elkayam, Ori, Hagin, David, Heshin-Bekenstein, Merav
Format: Article
Language:English
Subjects:
Adolescent
Antibodies, Viral - blood
Antibodies, Viral - immunology
Autoimmune Diseases - immunology
BNT162 Vaccine - immunology
CD4-Positive T-Lymphocytes - immunology
Child
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 Vaccines - immunology
Female
Humans
Immunity, Cellular
Immunity, Humoral - immunology
Interferon-gamma - immunology
Longitudinal Studies
Male
Prospective Studies
Rheumatic Diseases - immunology
SARS-CoV-2 - immunology
Spike Glycoprotein, Coronavirus - immunology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This paper aims to compare the cellular immune response to the SARS-CoV-2 BNT162b2 vaccine of pediatric patients with autoimmune inflammatory rheumatic disease (pAIIRD) and healthy controls. A prospective longitudinal study was conducted between April 2021 and December 2022 at the Tel Aviv Medical Center. Children
ISSN:0009-9104
1365-2249
1365-2249
DOI:10.1093/cei/uxae044